Sino Biopharm Wins NMPA Nod for First-in-Class Osteoarthritis Drug Trial

Sino Biopharmaceutical ( (HK:1177) ) has shared an announcement.

Sino Biopharmaceutical’s subsidiary Beijing Tide Pharmaceutical has secured approval from China’s National Medical Products Administration to begin clinical trials of TRD221, a first-in-class complement protein modulator injection for osteoarthritis. Co-developed with the Institute of Materia Medica under the Chinese Academy of Medical Sciences, the complex polysaccharide drug is designed to modulate the complement system to reduce inflammation, protect chondrocytes and promote cartilage repair, addressing a condition that affects hundreds of millions of patients worldwide and is rising with aging populations.

Existing osteoarthritis treatments largely focus on pain relief and do not adequately slow disease progression or restore joint function, leaving substantial unmet clinical needs in a market where prevalence is particularly high among older adults in China. Preclinical animal studies indicate TRD221 can both alleviate pain and improve structural joint damage with a favorable safety profile, and management says the trial approval strengthens the group’s innovative pipeline in the surgical and analgesic segment while potentially offering a new therapeutic option that could enhance its competitive position in the osteoarthritis space.

The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.90 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

More about Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a Hong Kong-listed pharmaceutical group focused on the research, development, manufacturing and commercialization of innovative drugs, particularly in areas such as surgery and analgesia. Through subsidiaries including Beijing Tide Pharmaceutical, the company targets large chronic disease markets in China and globally, leveraging partnerships with leading research institutes.

Average Trading Volume: 65,156,692

Technical Sentiment Signal: Buy

Current Market Cap: HK$108.9B

Find detailed analytics on 1177 stock on TipRanks’ Stock Analysis page.